Sign In
Buy JAZZ
$240.06
+9.13 (+3.95%)
At Close: Jun 04, 2026
Strength Seen in Jazz (JAZZ): Can Its 9% Jump Turn into More Strength?
07:28am, Tuesday, 11'th Jan 2022 Zacks Investment Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Jazz (JAZZ): Can Its 9% Jump Turn into More Strength?
03:53am, Tuesday, 11'th Jan 2022
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Jazz expects $5B in revenue in 2025, 5 new product launches by end of decade
01:48pm, Monday, 10'th Jan 2022 Seeking Alpha
Jazz Pharmaceuticals has unveiled an initiative called Vision 2025 with goals to boost revenue and increase the number of approved drugs.Two of the key goals are to generate…
20 cheap value stocks that Wall Street expects to rise up to 58%
06:28pm, Saturday, 08'th Jan 2022 MarketWatch
Value stocks have been performing better than growth stocks over the past month. Even so, they still look unusually cheap relative to growth stocks.
Jazz owner Smith, 76ers part owner Blitzer buying RSL | AP News
10:45pm, Wednesday, 05'th Jan 2022 Associated Press
SALT LAKE CITY (AP) Major League Soccer has approved the sale of Real Salt Lake to David Blitzer and Smith Entertainment Group. Blitzer also has an ownership stake in the NBA''s Philadelphia 76ers, the NHL''s New Jersey Devils and the Premier League''s Crystal Palace.
JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia
05:38pm, Tuesday, 04'th Jan 2022 Zacks Investment Research
The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.
Top Stocks To Invest In 2022? 4 Health Care Stocks To Check Out
04:30pm, Tuesday, 04'th Jan 2022
Health care stocks to watch as coronavirus cases show no signs of slowing down.
JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia
01:50pm, Tuesday, 04'th Jan 2022
The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.
The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives
01:10pm, Tuesday, 04'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Liquidia Appoints Pharma Industry Veteran Roger Jeffs As CEO
Liquidia Corporation (NASDAQ: LQDA) annou
A Peek Into The Markets: US Stock Futures Up Ahead Of Manufacturing Report
10:24am, Tuesday, 04'th Jan 2022 Benzinga
Pre-open movers
U.S. stock futures traded higher in early pre-market trade after the Dow Jones and S&P 500 closed at fresh highs on the first trading day of new year. Investors are awaiting earnings r
5 Stocks To Watch For January 4, 2022
10:04am, Tuesday, 04'th Jan 2022 Benzinga
Some of the stocks that may grab investor focus today are:
Wall Street expects SMART Global Holdings, Inc. (NASDAQ: SGH) to report quarterly earnings at $2.00 per share on revenue of $460.17 million
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
04:15pm, Monday, 03'rd Jan 2022
DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40th Annual J.P.
Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study
02:33pm, Friday, 31'st Dec 2021 Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.
Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study
10:43am, Friday, 31'st Dec 2021
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.
Jazz Pharmaceuticals Begins Enrollment For Clinical Trial To Evaluate JZP150 For Adults With PTSD
06:11pm, Thursday, 30'th Dec 2021 Benzinga
Biopharmaceutical company Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced Thursday that it has enrolled the first patient in its Phase 2 clinical trial evaluating the safety and efficacy of JZP150,
